A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...